Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs
Public ClinicalTrials.gov record NCT04924803. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Community Developed Technology-Based Messaging to Increase SARS-CoV-2 Vaccine Uptake Among People Who Inject Drugs
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
People who inject drugs (PWID) experience disproportionate risk of being infected with SARS-CoV-2, the virus that causes COVID-19, yet due to stigma, fear of mistreatment, and other factors, PWID are far less likely to be vaccinated compared to other populations. In response, we propose to continue our collaboration with a prominent community based organization serving African American and Latino PWID. Our project will explore baseline hesitancy to vaccinate among PWID, identify barriers to vaccination, and then develop and evaluate messaging designed to increase COVID-19 vaccination among our target population of PWID through a clinical trial.
Study identification
- NCT ID
- NCT04924803
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 545 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 20, 2022
- Primary completion
- Nov 24, 2025
- Completion
- Feb 26, 2026
- Last update posted
- Mar 20, 2025
2022 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| OnPoint NYC | New York | New York | 10035 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Covid19 trials
Other public records listing Covid19. Sorted by last update posted; newest first. Not a recommendation.
- NCT04652115: Defibrotide for the Treatment of Severe COVID-19 Recruiting
- NCT03305341: Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix Active, not recruiting
- NCT04956445: Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development Recruiting
- NCT04815096: Imaging Immune Activation in COVID-19 Recruiting
- NCT04910269: Outpatient Treatment With Anti-Coronavirus Immunoglobulin Recruiting
- NCT04896606: SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04924803, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 20, 2025 · Synced Aug 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04924803 live on ClinicalTrials.gov.